KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD
The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2021 KDIGO (Kidney Disease: Improving Global Outcomes) guideline for the management of blood pressure in chronic kidney disease (CKD). This commentary is the product of that work group and presents the recomme...
Gespeichert in:
| Veröffentlicht in: | American journal of kidney diseases 2022-03, Vol.79 (3), p.311-327 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 327 |
|---|---|
| container_issue | 3 |
| container_start_page | 311 |
| container_title | American journal of kidney diseases |
| container_volume | 79 |
| creator | Drawz, Paul E. Beddhu, Srinivasan Bignall, O.N. Ray Cohen, Jordana B. Flynn, Joseph T. Ku, Elaine Rahman, Mahboob Thomas, George Weir, Matthew R. Whelton, Paul K. |
| description | The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2021 KDIGO (Kidney Disease: Improving Global Outcomes) guideline for the management of blood pressure in chronic kidney disease (CKD). This commentary is the product of that work group and presents the recommendations and practice points from the KDIGO guideline in the context of US clinical practice. A critical addition to the KDIGO guideline is the recommendation for accurate assessment of blood pressure using standardized office blood pressure measurement. In the general adult population with CKD, KDIGO recommends a goal systolic blood pressure less than 120 mm Hg on the basis of results from the Systolic Blood Pressure Intervention Trial (SPRINT) and secondary analyses of the Action to Control Cardiovascular Risk in Diabetes-Blood Pressure (ACCORD-BP) trial. The KDOQI work group agreed with most of the recommendations while highlighting the weak evidence base especially for patients with diabetes and advanced CKD. |
| doi_str_mv | 10.1053/j.ajkd.2021.09.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2622283239</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638621009495</els_id><sourcerecordid>2622283239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-aac9aac777e08a1fcbd2ea0619449726d4c55339291b3af3218ba3ff008a91b63</originalsourceid><addsrcrecordid>eNp9kMFu1DAQQC0EarelP9AD8pFLwtjeOLHUC2TbZbVFC4KeLa8zKd4mcWsnSP17HLZw5GCNNHrzJD9CLhnkDArx4ZCbw0OTc-AsB5UDE6_IghVcZLIS1WuyAF7yTIpKnpKzGA8AoISUJ-RUFCCFAL4g_Xa1-7ahd99p7fseh9GEZ-oHOv5EOovpdrVZ72jducFZ09GvwdjRWaTryTWYtkhbH_7gX8xg7nF2UN_ST533TcIxxikgdQOtt6u35E1ruogXL_Oc3N1c_6g_Z7e79ab-eJvZJcCYGWNVemVZIlSGtXbfcDQgmVouVclls7RFIYTiiu2FaQVn1d6ItoVEp5UU5-T90fsY_NOEcdS9ixa7zgzop6i55JxXgguVUH5EbfAxBmz1Y3B9qqAZ6DmzPug5s55raFA6ZU5H7178077H5t_J364JuDoCmH75y2HQ0TocLDYuoB11493__L8BUDGLhA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2622283239</pqid></control><display><type>article</type><title>KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Drawz, Paul E. ; Beddhu, Srinivasan ; Bignall, O.N. Ray ; Cohen, Jordana B. ; Flynn, Joseph T. ; Ku, Elaine ; Rahman, Mahboob ; Thomas, George ; Weir, Matthew R. ; Whelton, Paul K.</creator><creatorcontrib>Drawz, Paul E. ; Beddhu, Srinivasan ; Bignall, O.N. Ray ; Cohen, Jordana B. ; Flynn, Joseph T. ; Ku, Elaine ; Rahman, Mahboob ; Thomas, George ; Weir, Matthew R. ; Whelton, Paul K.</creatorcontrib><description>The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2021 KDIGO (Kidney Disease: Improving Global Outcomes) guideline for the management of blood pressure in chronic kidney disease (CKD). This commentary is the product of that work group and presents the recommendations and practice points from the KDIGO guideline in the context of US clinical practice. A critical addition to the KDIGO guideline is the recommendation for accurate assessment of blood pressure using standardized office blood pressure measurement. In the general adult population with CKD, KDIGO recommends a goal systolic blood pressure less than 120 mm Hg on the basis of results from the Systolic Blood Pressure Intervention Trial (SPRINT) and secondary analyses of the Action to Control Cardiovascular Risk in Diabetes-Blood Pressure (ACCORD-BP) trial. The KDOQI work group agreed with most of the recommendations while highlighting the weak evidence base especially for patients with diabetes and advanced CKD.</description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2021.09.013</identifier><identifier>PMID: 35063302</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Blood Pressure ; Blood pressure (BP) ; Blood Pressure Determination ; BP control ; chronic kidney disease (CKD) ; commentary evidence-based recommendation ; diabetes ; dialysis ; end-stage kidney disease (ESKD) ; guideline implementation ; guidelines ; Humans ; hypertension ; Kidney ; nephrology best practices ; pediatric ; Renal Insufficiency, Chronic - complications ; transplant</subject><ispartof>American journal of kidney diseases, 2022-03, Vol.79 (3), p.311-327</ispartof><rights>2021 National Kidney Foundation, Inc.</rights><rights>Copyright © 2021 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-aac9aac777e08a1fcbd2ea0619449726d4c55339291b3af3218ba3ff008a91b63</citedby><cites>FETCH-LOGICAL-c400t-aac9aac777e08a1fcbd2ea0619449726d4c55339291b3af3218ba3ff008a91b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.ajkd.2021.09.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3554,27933,27934,46004</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35063302$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Drawz, Paul E.</creatorcontrib><creatorcontrib>Beddhu, Srinivasan</creatorcontrib><creatorcontrib>Bignall, O.N. Ray</creatorcontrib><creatorcontrib>Cohen, Jordana B.</creatorcontrib><creatorcontrib>Flynn, Joseph T.</creatorcontrib><creatorcontrib>Ku, Elaine</creatorcontrib><creatorcontrib>Rahman, Mahboob</creatorcontrib><creatorcontrib>Thomas, George</creatorcontrib><creatorcontrib>Weir, Matthew R.</creatorcontrib><creatorcontrib>Whelton, Paul K.</creatorcontrib><title>KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description>The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2021 KDIGO (Kidney Disease: Improving Global Outcomes) guideline for the management of blood pressure in chronic kidney disease (CKD). This commentary is the product of that work group and presents the recommendations and practice points from the KDIGO guideline in the context of US clinical practice. A critical addition to the KDIGO guideline is the recommendation for accurate assessment of blood pressure using standardized office blood pressure measurement. In the general adult population with CKD, KDIGO recommends a goal systolic blood pressure less than 120 mm Hg on the basis of results from the Systolic Blood Pressure Intervention Trial (SPRINT) and secondary analyses of the Action to Control Cardiovascular Risk in Diabetes-Blood Pressure (ACCORD-BP) trial. The KDOQI work group agreed with most of the recommendations while highlighting the weak evidence base especially for patients with diabetes and advanced CKD.</description><subject>Adult</subject><subject>Blood Pressure</subject><subject>Blood pressure (BP)</subject><subject>Blood Pressure Determination</subject><subject>BP control</subject><subject>chronic kidney disease (CKD)</subject><subject>commentary evidence-based recommendation</subject><subject>diabetes</subject><subject>dialysis</subject><subject>end-stage kidney disease (ESKD)</subject><subject>guideline implementation</subject><subject>guidelines</subject><subject>Humans</subject><subject>hypertension</subject><subject>Kidney</subject><subject>nephrology best practices</subject><subject>pediatric</subject><subject>Renal Insufficiency, Chronic - complications</subject><subject>transplant</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFu1DAQQC0EarelP9AD8pFLwtjeOLHUC2TbZbVFC4KeLa8zKd4mcWsnSP17HLZw5GCNNHrzJD9CLhnkDArx4ZCbw0OTc-AsB5UDE6_IghVcZLIS1WuyAF7yTIpKnpKzGA8AoISUJ-RUFCCFAL4g_Xa1-7ahd99p7fseh9GEZ-oHOv5EOovpdrVZ72jducFZ09GvwdjRWaTryTWYtkhbH_7gX8xg7nF2UN_ST533TcIxxikgdQOtt6u35E1ruogXL_Oc3N1c_6g_Z7e79ab-eJvZJcCYGWNVemVZIlSGtXbfcDQgmVouVclls7RFIYTiiu2FaQVn1d6ItoVEp5UU5-T90fsY_NOEcdS9ixa7zgzop6i55JxXgguVUH5EbfAxBmz1Y3B9qqAZ6DmzPug5s55raFA6ZU5H7178077H5t_J364JuDoCmH75y2HQ0TocLDYuoB11493__L8BUDGLhA</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Drawz, Paul E.</creator><creator>Beddhu, Srinivasan</creator><creator>Bignall, O.N. Ray</creator><creator>Cohen, Jordana B.</creator><creator>Flynn, Joseph T.</creator><creator>Ku, Elaine</creator><creator>Rahman, Mahboob</creator><creator>Thomas, George</creator><creator>Weir, Matthew R.</creator><creator>Whelton, Paul K.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202203</creationdate><title>KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD</title><author>Drawz, Paul E. ; Beddhu, Srinivasan ; Bignall, O.N. Ray ; Cohen, Jordana B. ; Flynn, Joseph T. ; Ku, Elaine ; Rahman, Mahboob ; Thomas, George ; Weir, Matthew R. ; Whelton, Paul K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-aac9aac777e08a1fcbd2ea0619449726d4c55339291b3af3218ba3ff008a91b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Blood Pressure</topic><topic>Blood pressure (BP)</topic><topic>Blood Pressure Determination</topic><topic>BP control</topic><topic>chronic kidney disease (CKD)</topic><topic>commentary evidence-based recommendation</topic><topic>diabetes</topic><topic>dialysis</topic><topic>end-stage kidney disease (ESKD)</topic><topic>guideline implementation</topic><topic>guidelines</topic><topic>Humans</topic><topic>hypertension</topic><topic>Kidney</topic><topic>nephrology best practices</topic><topic>pediatric</topic><topic>Renal Insufficiency, Chronic - complications</topic><topic>transplant</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Drawz, Paul E.</creatorcontrib><creatorcontrib>Beddhu, Srinivasan</creatorcontrib><creatorcontrib>Bignall, O.N. Ray</creatorcontrib><creatorcontrib>Cohen, Jordana B.</creatorcontrib><creatorcontrib>Flynn, Joseph T.</creatorcontrib><creatorcontrib>Ku, Elaine</creatorcontrib><creatorcontrib>Rahman, Mahboob</creatorcontrib><creatorcontrib>Thomas, George</creatorcontrib><creatorcontrib>Weir, Matthew R.</creatorcontrib><creatorcontrib>Whelton, Paul K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Drawz, Paul E.</au><au>Beddhu, Srinivasan</au><au>Bignall, O.N. Ray</au><au>Cohen, Jordana B.</au><au>Flynn, Joseph T.</au><au>Ku, Elaine</au><au>Rahman, Mahboob</au><au>Thomas, George</au><au>Weir, Matthew R.</au><au>Whelton, Paul K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2022-03</date><risdate>2022</risdate><volume>79</volume><issue>3</issue><spage>311</spage><epage>327</epage><pages>311-327</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract>The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2021 KDIGO (Kidney Disease: Improving Global Outcomes) guideline for the management of blood pressure in chronic kidney disease (CKD). This commentary is the product of that work group and presents the recommendations and practice points from the KDIGO guideline in the context of US clinical practice. A critical addition to the KDIGO guideline is the recommendation for accurate assessment of blood pressure using standardized office blood pressure measurement. In the general adult population with CKD, KDIGO recommends a goal systolic blood pressure less than 120 mm Hg on the basis of results from the Systolic Blood Pressure Intervention Trial (SPRINT) and secondary analyses of the Action to Control Cardiovascular Risk in Diabetes-Blood Pressure (ACCORD-BP) trial. The KDOQI work group agreed with most of the recommendations while highlighting the weak evidence base especially for patients with diabetes and advanced CKD.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35063302</pmid><doi>10.1053/j.ajkd.2021.09.013</doi><tpages>17</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0272-6386 |
| ispartof | American journal of kidney diseases, 2022-03, Vol.79 (3), p.311-327 |
| issn | 0272-6386 1523-6838 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2622283239 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Blood Pressure Blood pressure (BP) Blood Pressure Determination BP control chronic kidney disease (CKD) commentary evidence-based recommendation diabetes dialysis end-stage kidney disease (ESKD) guideline implementation guidelines Humans hypertension Kidney nephrology best practices pediatric Renal Insufficiency, Chronic - complications transplant |
| title | KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-29T23%3A40%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=KDOQI%20US%20Commentary%20on%20the%202021%20KDIGO%20Clinical%20Practice%20Guideline%20for%20the%20Management%20of%20Blood%20Pressure%20in%20CKD&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Drawz,%20Paul%20E.&rft.date=2022-03&rft.volume=79&rft.issue=3&rft.spage=311&rft.epage=327&rft.pages=311-327&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2021.09.013&rft_dat=%3Cproquest_cross%3E2622283239%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2622283239&rft_id=info:pmid/35063302&rft_els_id=S0272638621009495&rfr_iscdi=true |